Der sås en øget incidens af tumorer i det lymferetikulære system, lunge, brystvorte og hud hos mus, der blev behandlet med azacitidin, administreret intraperitonealt i 50 uger.
An increased incidence of tumours in the lymphoreticular system, lung, mammary gland, and skin was seen in mice treated with azacitidine administered intraperitoneally for 50 weeks.